摘要
目的评价DC-CIK细胞免疫联合干扰素治疗肾细胞癌的临床疗效。方法选取2016年3月至2018年3月于本院行腹腔镜肾癌手术的肾细胞癌患者80例作为研究对象,随机分为治疗组和对照组,每组40例,治疗组给予DC-CIK联合干扰素治疗,对照组单一使用干扰素治疗。比较两组临床疗效,治疗前后免疫功能、生活质量、不良反应及生存期情况。结果治疗组治疗总有效率明显高于对照组(P<0.05);治疗后,治疗组免疫功能和KPS评分均明显高于对照组(P<0.05),治疗组免疫功能较治疗前明显好转(P<0.05);治疗组平均生存期为(41.6±3.1)个月,对照组为(39.3±2.9)个月,两组比较差异有统计学意义(P<0.05);治疗组出现不良反应6例(15.0%),对照组5例(12.5%),差异无统计学意义。结论DC-CIK细胞免疫治疗联合干扰素较单一干扰素治疗肾细胞癌更具优势,安全性高,值得临床推广应用。
Objective To evaluate the safety and therapeutic effects of DC-CIK cells combined with interferon treatment in renal cell carcinoma patients.Methods 80 patients with renal cell carcinoma who underwent laparoscopic renal cancer surgery in our hospital from March 2016 to March 2018 were selected as the research subjects,and they were randomly divided into treatment group and control group,with 40 cases in each group.The treatment group treated DC-CIK cells combined with interferon and the control group was treated single interferon.The clinical efficacy,immune function,quality of life,adverse reactions and survival difference were compared between the two groups before and after treatment.Results The total effective rate of treatment in the treatment group was significantly higher than that in the control group(P<0.05);after treatment,the immune function and KPS score of the treatment group were significantly higher than those in the control group(P<0.05),and the immune function of the treatment group was significantly better than before treatment(P<0.05);the average survival time of the treatment group was(41.6±3.1)months,and the control group was(39.3±2.9)months,the difference between the two groups was statistically significant(P<0.05);adverse reactions occurred in 6 cases(15.0%)in the treatment group and 5 cases(12.5%)in the control group,the difference was not statistically significant.Conclusion DC-CIK cell combined with interferon has more advantages than single interferon in the treatment of renal cell carcinoma,with high safety,and it is worthy of clinical application.
作者
李勋钢
张文圣
颜小平
LI Xungang;ZHANG Wensheng;YAN Xiaoping(Department of Urology,First People's Hospital of Jiujiang(Jiujiang Hospital Affiliated to Nanchang University),Jiujiang,Jiangxi 332000)
出处
《当代医学》
2021年第6期46-48,共3页
Contemporary Medicine
基金
九江市科技支撑计划项目(20160104)。
